SynthesisFrontiers in medicine2025
Perioperative dexmedetomidine and renal outcomes in adult cardiac surgery: an updated systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Update on Perioperative Prevention of Cardiac Surgery-Associated Acute Kidney Injury.Journal of clinical medicine · 2026Review
- Preventing pediatric acute kidney injury: is it even possible?Pediatric nephrology (Berlin, Germany) · 2026Review
- Pathological triad of perioperative acute kidney injury: renal microcirculatory hypoxia, mitochondrial damage, and immuno-metabolic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is a common complication following cardiac surgery, associated with increased morbidity and mortality. Dexmedetomidine (DEX), a highly selective α-2 adrenoceptor agonist, has shown potential renal protective effects, but evidence remains inconsistent. This study aims to evaluate the efficacy of DEX in preventing AKI and improving renal outcomes in cardiac surgery patients through a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: A comprehensive search of PubMed, Cochrane Library, Embase, and Web of Science was conducted until April 2025. PICOS criteria were applied to select studies comparing DEX with placebo/normal saline in cardiac surgery patients. Primary outcomes included AKI incidence; secondary outcomes encompassed intraoperative parameters, postoperative recovery, and complications. Results: Bibliometric analysis highlighted China and the USA as leading contributors, with emerging trends in pediatric and mechanistic research. Among 16 RCTs ( Conclusion: DEX demonstrates significant renal protection and improves postoperative recovery in cardiac surgery patients, though optimal dosing requires further investigation. These findings support its integration into perioperative protocols but underscore the need for standardized dosing regimens. Systematic review registration: Identifier, INPLASY2025120019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.